David Borges Sells 906 Shares of Omeros (NASDAQ:OMER) Stock

Key Points

• Omeros CAO David Borges sold 906 shares at an average price of $19.10, totaling $17,304.60. The Rule 10b5-1 transaction reduced his direct ownership by 13.3% to 5,906 shares.
• Omeros shares traded near their 12-month high at $19.28, with a $1.40 billion market capitalization. The stock has risen substantially from its 12-month low of $3.94.
• The company reported quarterly EPS of $0.02, beating the $0.27 loss analysts expected, while revenue of $28.53 million also exceeded estimates. Analysts maintain a consensus “Moderate Buy” rating with an average price target of $38.00.

Omeros Corporation (NASDAQ:OMER - Get Free Report) CAO David Borges sold 906 shares of the stock in a transaction that occurred on Monday, August 24th. The shares were sold at an average price of $19.10, for a total value of $17,304.60. Following the completion of the sale, the chief accounting officer directly owned 5,906 shares of the company's stock, valued at approximately $112,804.60. The trade was a 13.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Omeros Stock Performance

OMER traded down $0.04 during trading on Tuesday, reaching $19.28. 1,314,611 shares of the stock were exchanged, compared to its average volume of 1,716,966. The stock's 50 day moving average price is $11.93 and its two-hundred day moving average price is $11.81. Omeros Corporation has a twelve month low of $3.94 and a twelve month high of $19.65. The stock has a market cap of $1.40 billion, a P/E ratio of 15.06 and a beta of 2.54.

Omeros (NASDAQ:OMER - Get Free Report) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.29. The firm had revenue of $28.53 million during the quarter, compared to the consensus estimate of $12.69 million. Equities research analysts predict that Omeros Corporation will post -0.37 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Omeros

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. UBS Group AG increased its stake in shares of Omeros by 213.5% in the fourth quarter. UBS Group AG now owns 2,222,982 shares of the biopharmaceutical company's stock valued at $38,180,000 after buying an additional 1,513,893 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Omeros by 85.2% in the first quarter. Dimensional Fund Advisors LP now owns 179,594 shares of the biopharmaceutical company's stock worth $1,897,000 after acquiring an additional 82,646 shares during the period. Corient Private Wealth LLC increased its position in Omeros by 13.0% during the 4th quarter. Corient Private Wealth LLC now owns 688,025 shares of the biopharmaceutical company's stock valued at $11,817,000 after purchasing an additional 79,263 shares during the period. Quantinno Capital Management LP lifted its position in shares of Omeros by 145.4% in the 1st quarter. Quantinno Capital Management LP now owns 61,541 shares of the biopharmaceutical company's stock worth $650,000 after purchasing an additional 36,467 shares during the period. Finally, Compass Financial Management LLC acquired a new stake in shares of Omeros during the second quarter worth $312,000. 48.79% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. Zacks Research cut Omeros from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 13th. HC Wainwright reissued a "buy" rating on shares of Omeros in a research report on Monday, July 27th. Weiss Ratings upgraded shares of Omeros from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Wednesday, August 5th. Finally, Wall Street Zen upgraded shares of Omeros from a "hold" rating to a "buy" rating in a research note on Saturday, August 15th. One equities research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $38.00.

Omeros Company Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company's research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros's portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros's first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source